The UCLA Center in Early Detection of Liver Cancer

项目总结/摘要 肝细胞癌（HCC）是肝细胞癌患者的主要死亡原因。这种肿瘤与 90%以上的病例为肝硬化。在早期准确检测HCC的方法将大大 提高我们管理和治疗疾病的能力。加州大学洛杉矶分校中心旨在开发一个有效的， 肝癌的早期诊断方法有哪些？我们的团队由翻译和 在早期检测、生物标志物、癌症领域具有多学科专业知识的临床研究人员 监视、成像和生物储存库。我们将重点关注血液中的循环肿瘤DNA（ctDNA）。ctDNA 携带癌症特异性遗传和表观遗传畸变，这使得癌症的非侵入性“液体活检”成为可能。 诊断.我们的诊断测试基于cfDNA的DNA甲基化模式。我们的集成计算 实验技术可以显著提高诊断能力，同时显著降低成本。 本研究的主要目的是：（1）建立一个慢性阻塞性肺疾病患者的纵向队列研究。肝硬化患者 将每6个月接受一次超声成像筛查和血液样本采集。UCLA肝脏 每年约有1200名患者就诊。(2)我们将建立一个最先进的生物标本库， 包括来自群组中个体的血浆、来自切除后的肝肿瘤的组织和切除后的肝损伤。 肝移植(3)我们将进行2期临床试验验证和3期早期检测验证 进行诊断测试(4)我们将为跨网络合作活动做出贡献。

PROJECT SUMMARY / ABSTRACT Hepatocellular carcinoma (HCC) is a major cause of death in cirrhotic patients. This neoplasm is associated with liver cirrhosis in more than 90% of cases. A method of detecting HCC accurately in its early stages would greatly improve our ability to manage and treat the disease. The UCLA Center aims to develop an effective and affordable blood-based method for the early detection of liver cancer. Our team consists of translational and clinical researchers with multi-disciplinary expertise in the areas of early detection, biomarkers, cancer surveillance, imaging, and biorepositories. We will focus on circulating tumor DNA (ctDNA) in the blood. ctDNA carryies cancer-specific genetic and epigenetic aberrations, which enable a noninvasive `liquid biopsy' for cancer diagnosis. Our diagnostic test is based on the DNA methylation patterns of cfDNA. Our integrated computational and experimental technologies can significantly boost the diagnostic power while dramatically reducing the cost. We have the following aims: (1) We will establish a longitudinal cohort of cirrhotic patients. The cirrhotic patients will be subject to ultrasound imaging screening and blood sample collection every 6 months. The UCLA liver clinic sees ~1200 cirrhotic patients per year. (2) We will establish a state-of-the-art biospecimen repository that includes plasma from individuals in the cohort, tissue from liver tumors after resection, and cirrhotic lesions after liver transplantation. (3) We will perform Phase 2 clinical assay validation and Phase 3 early detection validation for the diagnostic test. (4) We will contribute to the collaborative trans-network activities.